Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TCDIFLU

Financiado

Cerrado

Impact of adjuvants on T cell differentiation after Influenza Vaccination analyz...

Impact of adjuvants on T cell differentiation after Influenza Vaccination analyzed at the Single Cell Level "Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizing antibodies are the key for protection against flu infection, but flu-specific CD4+ and... ver más

28/02/2013

GSK Vaccines Srl

180K€

Presupuesto del proyecto: 180K€

Líder del proyecto

GlaxoSmithKline Vaccines Srl No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-02-28 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GSK Vaccines Srl

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2013-48754-C2-1-R MECHANISMS OF INFECTED CELL RECOGNITION AND IN VIVO CONTROL... 411K€ Cerrado

HIVINNATE Innate sensing of HIV and immune responses 2M€ Cerrado

PROTECTC Identify novel pathways to enhance the induction of protecti... 1M€ Cerrado

UNFITHIV Understanding the importance of viral Fitness Impairment aft... 279K€ Cerrado

CUT'HIVAC Cutaneous and Mucosal HIV Vaccination 15M€ Cerrado

GutBCells Cellular Dynamics of Intestinal Antibody Mediated Immune Res... 1M€ Cerrado

Líder del proyecto

GlaxoSmithKline Vaccines Srl No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 180K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizing antibodies are the key for protection against flu infection, but flu-specific CD4+ and CD8+ T cells play a significant role by providing help to B cells and in viral clearance, respectively. There are many vaccines against flu infection approved for human use. The generally effective seasonal vaccines, however, have a number of deficiencies, including the need to repeat the injections every year with a newly updated vaccine, which provides only antibody-dominated subtype-specific protection. Adjuvants are used to enhance the immune response to a vaccine. They lead to different types of cell-mediated immune responses. The T cell type (Th1, Th2, cytotoxic) and the magnitude of the immune response discriminate between viral clearance and immunopathology. Particular T cell subpopulations (like Th1 IFN-γ or CD8+ perforin or Fas expressing cells) may be responsible for protection after infection or vaccination and may give correlation to protective adjuvants. Studies of T cells using assays analyzing entire cell populations are not suitable to uncover these cell populations. We propose a detailed T cell differentiation profiling of CD4+ and CD8+ T lymphocytes at the single cell level after flu vaccination using the quantitative single cell multiplex RT-PCR method. Individual T lymphocytes purified from the vaccination site draining lymph nodes will be analyzed for the presence of up to twenty important differentiation markers. The results will be verified by additional methods, like flow cytometry or confocal microscopy. This project will reveal the presence of T cell subpopulations possibly correlated to protection after flu infection with mouse-adapted PR8 influenza strain or immunization with seasonal flu vaccine, with special consideration on the effect of adjuvants."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores